{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:01:46Z","timestamp":1784570506359,"version":"3.55.0"},"reference-count":131,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T00:00:00Z","timestamp":1779667200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":56,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"USERN Foundation Houston TX USA","award":["2025.0820"],"award-info":[{"award-number":["2025.0820"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0820"],"award-info":[{"award-number":["2025.0820"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0820"],"award-info":[{"award-number":["2025.0820"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0820"],"award-info":[{"award-number":["2025.0820"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0820"],"award-info":[{"award-number":["2025.0820"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0820"],"award-info":[{"award-number":["2025.0820"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0820"],"award-info":[{"award-number":["2025.0820"]}]},{"name":"USERN Foundation Houston TX USA","award":["2025.0820"],"award-info":[{"award-number":["2025.0820"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Cell Int"],"DOI":"10.1186\/s12935-026-04345-9","type":"journal-article","created":{"date-parts":[[2026,5,25]],"date-time":"2026-05-25T05:03:59Z","timestamp":1779685439000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting the NKG2D axis in head and neck squamous cell carcinoma: from molecular insights to clinical applications"],"prefix":"10.1186","volume":"26","author":[{"given":"Parsa","family":"Alijanizadeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahshid","family":"Shahmoradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirhossein","family":"Kamroo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara","family":"Shahmoradi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Tajafrooz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pegah","family":"khodaee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niloufar","family":"Yazdanpanah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiarash","family":"Saleki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nima","family":"Rezaei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,25]]},"reference":[{"key":"4345_CR1","unstructured":"Cancer incidence. Both sexes, In 2022 Available from: https:\/\/gco.iarc.fr\/today\/en\/dataviz\/tables?mode=cancer&group_populations=1&multiple_populations=1"},{"issue":"1","key":"4345_CR2","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1146\/annurev.pathol.4.110807.092158","volume":"4","author":"SI Pai","year":"2009","unstructured":"Pai SI, Westra WH. Molecular pathology of head and neck cancer: implications for diagnosis, prognosis, and treatment. Annual Review of Pathology: Mechanisms of Disease. 2009 Feb 28;4(1):49-70. https:\/\/doi.org\/10.1146\/annurev.pathol.4.110807.092158","journal-title":"Annual Review of Pathology: Mechanisms of Disease."},{"issue":"11","key":"4345_CR3","doi-asserted-by":"publisher","first-page":"1282","DOI":"10.1001\/archotol.128.11.1282","volume":"128","author":"MA Medow","year":"2002","unstructured":"Medow MA, Weed HG, Schuller DE. Simple predictors of survival in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2002;128(11):1282\u20136.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"issue":"1","key":"4345_CR4","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1186\/s12964-023-01070-y","volume":"21","author":"Y Xiang","year":"2023","unstructured":"Xiang Y, Gong M, Deng Y, Wang H, Ye D. T cell effects and mechanisms in immunotherapy of head and neck tumors. Cell Communication Signal. 2023;21(1). https:\/\/doi.org\/10.1186\/s12964-023-01070-y","journal-title":"Cell Communication and Signaling."},{"issue":"6","key":"4345_CR5","doi-asserted-by":"publisher","first-page":"1642","DOI":"10.3390\/cancers15061642","volume":"15","author":"K Starska-Kowarska","year":"2023","unstructured":"Starska-Kowarska K. The role of different immunocompetent cell populations in the pathogenesis of head and neck cancer\u2014regulatory mechanisms of pro- and anti-cancer activity and their impact on immunotherapy. Cancers Basel. 2023;15(6):1642.","journal-title":"Cancers Basel"},{"issue":"4","key":"4345_CR6","first-page":"493","volume":"20","author":"L Xie","year":"2007","unstructured":"Xie L, Pries R, Kesselring R, Wulff S, Wollenberg B. Head and neck cancer triggers the internalization of TLR3 in natural killer cells. Int J Mol Med. 2007;20(4):493\u20139.","journal-title":"Int J Mol Med"},{"key":"4345_CR7","doi-asserted-by":"crossref","unstructured":"Kansy BA, Lee SC, Ferris RL. Immunology of head and neck cancer. Head and Neck Cancer: Multimodality Management, Second Edition2016. pp. 133\u2009\u2013\u200948.","DOI":"10.1007\/978-3-319-27601-4_6"},{"issue":"7","key":"4345_CR8","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1002\/mc.23162","volume":"59","author":"SM Chen","year":"2020","unstructured":"Chen SM, Krinsky AL, Woolaver RA, Wang X, Chen Z, Wang JH. Tumor immune microenvironment in head and neck cancers. Mol Carcinog. 2020;59(7):766\u201374.","journal-title":"Mol Carcinog"},{"issue":"12","key":"4345_CR9","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.3390\/cancers14122884","volume":"14","author":"N Kondoh","year":"2022","unstructured":"Kondoh N, Mizuno-Kamiya M. The role of immune modulatory cytokines in the tumor microenvironments of head and neck squamous cell carcinomas. Cancers Basel. 2022;14(12):2884.","journal-title":"Cancers Basel"},{"issue":"1","key":"4345_CR10","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1186\/s13046-023-02691-4","volume":"42","author":"K Okuyama","year":"2023","unstructured":"Okuyama K, Naruse T, Yanamoto S. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma. J Exp Clin Cancer Res. 2023;42(1):114.","journal-title":"J Exp Clin Cancer Res"},{"key":"4345_CR11","doi-asserted-by":"publisher","first-page":"532","DOI":"10.3389\/fonc.2018.00532","volume":"8","author":"W Lin","year":"2018","unstructured":"Lin W, Chen M, Hong L, Zhao H, Chen Q. Crosstalk between PD-1\/PD-L1 blockade and its combinatorial therapies in tumor immune microenvironment: a focus on HNSCC. Front Oncol. 2018;8:532.","journal-title":"Front Oncol"},{"issue":"7","key":"4345_CR12","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1016\/j.ymthe.2023.02.023","volume":"31","author":"S Wang","year":"2023","unstructured":"Wang S, Wu Z-Z, Zhu S-W, Wan S-C, Zhang M-J, Zhang B-X, et al. CTLA-4 blockade induces tumor pyroptosis via CD8\u2009+\u2009T cells in head and neck squamous cell carcinoma. Mol Ther. 2023;31(7):2154\u201368.","journal-title":"Mol Ther"},{"key":"4345_CR13","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.oraloncology.2019.03.010","volume":"92","author":"S Greene","year":"2019","unstructured":"Greene S, Patel P, Allen CT. How patients with an intact immune system develop head and neck cancer. Oral Oncol. 2019;92:26\u201332.","journal-title":"Oral Oncol"},{"issue":"4","key":"4345_CR14","doi-asserted-by":"publisher","first-page":"e1397248","DOI":"10.1080\/2162402X.2017.1397248","volume":"7","author":"L Wu","year":"2018","unstructured":"Wu L, Yu G-T, Deng W-W, Mao L, Yang L-L, Ma S-R, et al. Anti-CD47 treatment enhances anti-tumor T-cell immunity and improves immunosuppressive environment in head and neck squamous cell carcinoma. Oncoimmunology. 2018;7(4):e1397248.","journal-title":"Oncoimmunology"},{"issue":"16","key":"4345_CR15","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.2217\/imt-2017-0125","volume":"9","author":"A Tosoni","year":"2017","unstructured":"Tosoni A, Franceschi E, Pasquini E, Lanese A, Donini E, Foschini MP, et al. Immunotherapy in head and neck cancer: Evidence and perspectives. Immunotherapy. 2017;9(16):1351\u20138.","journal-title":"Immunotherapy"},{"issue":"8","key":"4345_CR16","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/archotol.129.8.874","volume":"129","author":"R Feinmesser","year":"2003","unstructured":"Feinmesser R, Hardy B, Sadov R, Shwartz A, Chretien P, Feinmesser M. Report of a clinical trial in 12 patients with head and neck cancer treated intratumorally and peritumorally with Multikine. Arch Otolaryngol Head Neck Surg. 2003;129(8):874\u201381.","journal-title":"Arch Otolaryngol Head Neck Surg"},{"key":"4345_CR17","doi-asserted-by":"crossref","unstructured":"Weil S, Memmer S, Lechner A, Huppert V, Giannattasio A, Becker T et al. Natural killer group 2D ligand depletion reconstitutes natural killer cell immunosurveillance of head and neck squamous cell carcinoma. Frontiers in Immunology. 2017;8(APR).","DOI":"10.3389\/fimmu.2017.00387"},{"key":"4345_CR18","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.aai8904","volume":"10","author":"J Zuo","year":"2017","unstructured":"ZuoJ, Willcox CR, Mohammed F, Davey M, Hunter S, Khan K, et al. A disease-linked ULBP6 polymorphism inhibits NKG2D-mediated target cell killing by enhancing the stability of NKG2D ligand binding. Sci Signal. 2017;10:481: eaai8904. https:\/\/doi.org\/10.1126\/scisignal.aai8904","journal-title":"Sci Signal"},{"key":"4345_CR19","doi-asserted-by":"crossref","unstructured":"Stojanovic A, Correia MP, Cerwenka A. The NKG2D\/NKG2DL axis in the crosstalk between lymphoid and myeloid cells in health and disease. Frontiers in Immunology. 2018;9(APR).","DOI":"10.3389\/fimmu.2018.00827"},{"issue":"21","key":"4345_CR20","doi-asserted-by":"publisher","first-page":"3519","DOI":"10.1007\/s00018-011-0797-0","volume":"68","author":"B Zafirova","year":"2011","unstructured":"Zafirova B, Wensveen FM, Gulin M, Poli\u0107 B. Regulation of immune cell function and differentiation by the NKG2D receptor. Cell Mol Life Sci. 2011;68(21):3519\u201329.","journal-title":"Cell Mol Life Sci"},{"issue":"10","key":"4345_CR21","doi-asserted-by":"publisher","first-page":"6600","DOI":"10.4049\/jimmunol.0801214","volume":"182","author":"JE Butler","year":"2009","unstructured":"Butler JE, Moore MB, Presnell SR, Chan HW, Chalupny JN, Lutz CT. Proteasome regulation of ULBP1 transcription. J Immunol. 2009;182(10):6600\u20139.","journal-title":"J Immunol"},{"key":"4345_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1442673","author":"S Dong","year":"2024","unstructured":"Dong S, Zhao M, Zhu J, Li T, Yan M, Xing K, et al. Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1442673.","journal-title":"Front Immunol"},{"issue":"9","key":"4345_CR23","doi-asserted-by":"publisher","first-page":"5705","DOI":"10.1007\/s00432-022-04532-x","volume":"149","author":"J Lee","year":"2023","unstructured":"Lee J, Keam B, Park HR, Park JE, Kim S, Kim M, et al. Monalizumab efficacy correlates with HLA-E surface expression and NK cell activity in head and neck squamous carcinoma cell lines. J Cancer Res Clin Oncol. 2023;149(9):5705\u201315.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"4345_CR24","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1084\/jem.173.4.1017","volume":"173","author":"JP Houchins","year":"1991","unstructured":"Houchins JP, Yabe T, McSherry C, Bach FH. DNA sequence analysis of NKG2, a family of related cDNA clones encoding type II integral membrane proteins on human natural killer cells. J Exp Med. 1991;173(4):1017\u201320.","journal-title":"J Exp Med"},{"issue":"21","key":"4345_CR25","doi-asserted-by":"publisher","first-page":"7641","DOI":"10.1073\/pnas.0502439102","volume":"102","author":"D Garrity","year":"2005","unstructured":"Garrity D, Call ME, Feng J, Wucherpfennig KW. The activating NKG2D receptor assembles in the membrane with two signaling dimers into a hexameric structure. Proc Natl Acad Sci U S A. 2005;102(21):7641\u20136.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"4345_CR26","doi-asserted-by":"publisher","DOI":"10.1111\/imr.13435","volume":"329","author":"RA Mariuzza","year":"2025","unstructured":"Mariuzza RA, Singh P, Karade SS, Shahid S, Sharma VK. Recognition of self and viral ligands by NK cell receptors. Immunol Rev. 2025;329(1):e13435.","journal-title":"Immunol Rev"},{"key":"4345_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00476","volume":"9","author":"A Zingoni","year":"2018","unstructured":"Zingoni A, Molfetta R, Fionda C, Soriani A, Paolini R, Cippitelli M, et al. NKG2D and its ligands: one for all, all for one. Front Immunol. 2018;9:476.","journal-title":"Front Immunol"},{"key":"4345_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.coi.2018.02.004","volume":"51","author":"P Dhar","year":"2018","unstructured":"Dhar P, Wu JD. NKG2D and its ligands in cancer. Curr Opin Immunol. 2018;51:55\u201361.","journal-title":"Curr Opin Immunol"},{"issue":"1","key":"4345_CR29","doi-asserted-by":"publisher","first-page":"8664","DOI":"10.1038\/s41467-024-52913-2","volume":"15","author":"Y Charpak-Amikam","year":"2024","unstructured":"Charpak-Amikam Y, Kournos M, Kotzur R, Isaacson B, Bagad Brenner T, Gomez-Cesar E, et al. The activating receptor NKG2D is an anti-fungal pattern recognition receptor. Nat Commun. 2024;15(1):8664.","journal-title":"Nat Commun"},{"issue":"1","key":"4345_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12943-019-0956-8","volume":"18","author":"S Duan","year":"2019","unstructured":"Duan S, Guo W, Xu Z, He Y, Liang C, Mo Y, et al. Natural killer group 2D receptor and its ligands in cancer immune escape. Mol Cancer. 2019;18(1):29.","journal-title":"Mol Cancer"},{"key":"4345_CR31","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557644","volume":"16","author":"J Han","year":"2025","unstructured":"Han J, Wang Y, Chan GC, Chan WK. Designs of NKG2D-based immunotherapeutics for cancer. Front Immunol. 2025;16:1557644.","journal-title":"Front Immunol"},{"issue":"6","key":"4345_CR32","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.3390\/cells10061420","volume":"10","author":"J Siemaszko","year":"2021","unstructured":"Siemaszko J, Marzec-Przyszlak A, Bogunia-Kubik K. NKG2D natural killer cell receptor\u2014a short description and potential clinical applications. Cells. 2021;10(6):1420.","journal-title":"Cells"},{"issue":"3","key":"4345_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1016\/j.smim.2006.04.002","volume":"18","author":"S Malarkannan","year":"2006","unstructured":"Malarkannan S. The balancing act: inhibitory Ly49 regulate NKG2D-mediated NK cell functions. Semin Immunol. 2006;18(3):186\u201392.","journal-title":"Semin Immunol"},{"issue":"6383","key":"4345_CR34","doi-asserted-by":"publisher","first-page":"1537","DOI":"10.1126\/science.aao0505","volume":"359","author":"L Ferrari de Andrade","year":"2018","unstructured":"Ferrari de Andrade L, Tay RE, Pan D, Luoma AM, Ito Y, Badrinath S, et al. Antibody-mediated inhibition of MICA and MICB shedding promotes NK cell\u2013driven tumor immunity. Science. 2018;359(6383):1537\u201342.","journal-title":"Science"},{"issue":"1","key":"4345_CR35","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-73712-1","volume":"14","author":"H Toyoda","year":"2024","unstructured":"Toyoda H, Kuramasu A, Hosonuma M, Murayama M, Narikawa Y, Isobe J, et al. MHC class i polypeptide-related sequence b shedding modulates pancreatic tumor immunity via the activation of NKG2DLow t cells. Sci Rep. 2024;14(1):23401.","journal-title":"Sci Rep"},{"key":"4345_CR36","doi-asserted-by":"publisher","first-page":"105783","DOI":"10.1016\/j.pep.2020.105783","volume":"178","author":"Q Zhao","year":"2021","unstructured":"Zhao Q, Pang J, Yan F, Jiang Y, Cui D, Liu J, et al. Production of a novel bispecific protein ULBP1\u00d7CD19-scFv targeting the NKG2D receptor and CD19 to promote the activation of NK cells. Protein Exp Purif. 2021;178:105783.","journal-title":"Protein Exp Purif"},{"issue":"3","key":"4345_CR37","doi-asserted-by":"publisher","first-page":"e91133","DOI":"10.1371\/journal.pone.0091133","volume":"9","author":"R Wang","year":"2014","unstructured":"Wang R, Sun PD. Natural killer cell-mediated shedding of ULBP2. PLoS One. 2014;9(3):e91133.","journal-title":"PLoS One"},{"issue":"12","key":"4345_CR38","doi-asserted-by":"publisher","first-page":"8543","DOI":"10.1074\/jbc.M109.045906","volume":"285","author":"L Fern\u00e1ndez-Messina","year":"2010","unstructured":"Fern\u00e1ndez-Messina L, Ashiru O, Boutet P, Ag\u00fcera-Gonz\u00e1lez S, Skepper JN, Reyburn HT, et al. Differential mechanisms of shedding of the glycosylphosphatidylinositol (GPI)-anchored NKG2D ligands. J Biol Chem. 2010;285(12):8543\u201351.","journal-title":"J Biol Chem"},{"key":"4345_CR39","doi-asserted-by":"publisher","DOI":"10.3390\/biology12081079","author":"G Tan","year":"2023","unstructured":"Tan G, Spillane KM, Maher J. The role and regulation of the NKG2D\/NKG2D ligand system in cancer. Biology (Basel). 2023. https:\/\/doi.org\/10.3390\/biology12081079.","journal-title":"Biology (Basel)"},{"issue":"1","key":"4345_CR40","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1146\/annurev-immunol-101819-074948","volume":"39","author":"AM Mujal","year":"2021","unstructured":"Mujal AM, Delconte RB, Sun JC. Natural killer cells: from innate to adaptive features. Annu Rev Immunol. 2021;39(1):417\u201347.","journal-title":"Annu Rev Immunol"},{"issue":"9","key":"4345_CR41","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s43018-023-00600-4","volume":"4","author":"EC Lerner","year":"2023","unstructured":"Lerner EC, Woroniecka KI, D\u2019Anniballe VM, Wilkinson DS, Mohan AA, Lorrey SJ, et al. CD8\u2009+\u2009t cells maintain killing of MHC-I-negative tumor cells through the NKG2D\u2013NKG2DL axis. Nat Cancer. 2023;4(9):1258\u201372.","journal-title":"Nat Cancer"},{"key":"4345_CR42","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.868496","author":"D Tomaz","year":"2022","unstructured":"Tomaz D, Pereira PM, Guerra N, Dyson J, Gould K, Henriques R. Nanoscale colocalization of NK cell activating and inhibitory receptors controls signal integration. Front Immunol. 2022. https:\/\/doi.org\/10.3389\/fimmu.2022.868496.","journal-title":"Front Immunol"},{"issue":"6","key":"4345_CR43","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/S1074-7613(00)80222-8","volume":"12","author":"A Cerwenka","year":"2000","unstructured":"Cerwenka A, Bakker AB, McClanahan T, Wagner J, Wu J, Phillips JH, et al. Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice. Immunity. 2000;12(6):721\u20137.","journal-title":"Immunity"},{"issue":"7","key":"4345_CR44","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1002\/eji.201646805","volume":"47","author":"I Kavazovi\u0107","year":"2017","unstructured":"Kavazovi\u0107 I, Lenarti\u0107 M, Jelen\u010di\u0107 V, Jurkovi\u0107 S, Lemmermann NA, Jonji\u0107 S, et al. NKG2D stimulation of CD8\u2009+\u2009T cells during priming promotes their capacity to produce cytokines in response to viral infection in mice. Eur J Immunol. 2017;47(7):1123\u201335.","journal-title":"Eur J Immunol"},{"issue":"1","key":"4345_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms13930","volume":"8","author":"S Sheppard","year":"2017","unstructured":"Sheppard S, Guedes J, Mroz A, Zavitsanou A-M, Kudo H, Rothery SM, et al. The immunoreceptor NKG2D promotes tumour growth in a model of hepatocellular carcinoma. Nat Commun. 2017;8(1):13930.","journal-title":"Nat Commun"},{"issue":"12","key":"4345_CR46","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/ni857","volume":"3","author":"S Gilfillan","year":"2002","unstructured":"Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nat Immunol. 2002;3(12):1150\u20135.","journal-title":"Nat Immunol"},{"issue":"12","key":"4345_CR47","doi-asserted-by":"publisher","first-page":"1150","DOI":"10.1038\/ni857","volume":"3","author":"S Gilfillan","year":"2002","unstructured":"Gilfillan S, Ho EL, Cella M, Yokoyama WM, Colonna M. NKG2D recruits two distinct adapters to trigger NK cell activation and costimulation. Nature immunology. 2002 Dec;3(12):1150-5. https:\/\/doi.org\/10.1038\/ni857","journal-title":"Nature immunology."},{"issue":"5","key":"4345_CR48","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1038\/ni1325","volume":"7","author":"JL Upshaw","year":"2006","unstructured":"Upshaw JL, Arneson LN, Schoon RA, Dick CJ, Billadeau DD, Leibson PJ. NKG2D-mediated signaling requires a DAP10-bound Grb2-Vav1 intermediate and phosphatidylinositol-3-kinase in human natural killer cells. Nat Immunol. 2006;7(5):524\u201332.","journal-title":"Nat Immunol"},{"issue":"4","key":"4345_CR49","doi-asserted-by":"publisher","first-page":"2470","DOI":"10.4049\/jimmunol.173.4.2470","volume":"173","author":"DB Rosen","year":"2004","unstructured":"Rosen DB, Araki M, Hamerman JA, Chen T, Yamamura T, Lanier LL. A structural basis for the association of DAP12 with mouse, but not human, NKG2D. J Immunol. 2004;173(4):2470\u20138.","journal-title":"J Immunol"},{"issue":"1","key":"4345_CR50","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ymthe.2020.08.016","volume":"29","author":"Y-Y Ng","year":"2021","unstructured":"Ng Y-Y, Tay JC, Li Z, Wang J, Zhu J, Wang S. T cells expressing NKG2D CAR with a DAP12 signaling domain stimulate lower cytokine production while effective in tumor eradication. Mol Ther. 2021;29(1):75\u201385.","journal-title":"Mol Ther"},{"issue":"6","key":"4345_CR51","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1038\/ni930","volume":"4","author":"S Zompi","year":"2003","unstructured":"Zompi S, Hamerman JA, Ogasawara K, Schweighoffer E, Tybulewicz VL, Di Santo JP, et al. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat Immunol. 2003;4(6):565\u201372.","journal-title":"Nat Immunol"},{"issue":"4","key":"4345_CR52","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1016\/j.immuni.2008.02.016","volume":"28","author":"N Guerra","year":"2008","unstructured":"Guerra N, Tan YX, Joncker NT, Choy A, Gallardo F, Xiong N, et al. NKG2D-deficient mice are defective in tumor surveillance in models of spontaneous malignancy. Immunity. 2008;28(4):571\u201380.","journal-title":"Immunity"},{"issue":"21","key":"4345_CR53","doi-asserted-by":"publisher","first-page":"4819","DOI":"10.1158\/1078-0432.CCR-15-0845","volume":"21","author":"S Lu","year":"2015","unstructured":"Lu S, Zhang J, Liu D, Li G, Staveley-O\u2019Carroll KF, Li Z, et al. Nonblocking monoclonal antibody targeting soluble MIC revamps endogenous innate and adaptive antitumor responses and eliminates primary and metastatic tumors. Clin Cancer Res. 2015;21(21):4819\u201330.","journal-title":"Clin Cancer Res"},{"issue":"10","key":"4345_CR54","doi-asserted-by":"publisher","first-page":"e002980","DOI":"10.1136\/jitc-2021-002980","volume":"9","author":"C Zhang","year":"2021","unstructured":"ZhangC, R\u00f6der J, Scherer A, Bodden M, Serrahima JP, Bhatti A, Waldmann A, M\u00fcller N, Oberoi P, Wels WS. Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity. J Immunother Cancer. 2021;9(10):e002980. . https:\/\/doi.org\/10.1136\/jitc-2021-002980","journal-title":"J Immunother Cancer"},{"key":"4345_CR55","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2026.2622794","author":"M Glover","year":"2026","unstructured":"Glover M, Maher J, Davies DM. Harnessing the NKG2D immune surveillance pathway using engineered T-cells for the treatment of human disease. Hum Vaccin Immunother. 2026. https:\/\/doi.org\/10.1080\/21645515.2026.2622794.","journal-title":"Hum Vaccin Immunother"},{"issue":"5","key":"4345_CR56","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1182\/blood-2004-11-4365","volume":"106","author":"T Zhang","year":"2005","unstructured":"Zhang T, Lemoi BA, Sentman CL. Chimeric NK-receptor-bearing T cells mediate antitumor immunotherapy. Blood. 2005;106(5):1544\u201351.","journal-title":"Blood"},{"key":"4345_CR57","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1557644","author":"J Han","year":"2025","unstructured":"Han J, Wang Y, Chan GCF, Chan WK. Designs of NKG2D-based immunotherapeutics for cancer. Front Immunol. 2025. https:\/\/doi.org\/10.3389\/fimmu.2025.1557644.","journal-title":"Front Immunol"},{"issue":"10","key":"4345_CR58","doi-asserted-by":"publisher","first-page":"e1346766","DOI":"10.1080\/2162402X.2017.1346766","volume":"6","author":"A L\u00f3pez-Soto","year":"2017","unstructured":"L\u00f3pez-Soto A, Gonzalez S, Galluzzi L. Soluble NKG2D ligands limit the efficacy of immune checkpoint blockade. Oncoimmunology. 2017;6(10):e1346766.","journal-title":"Oncoimmunology"},{"key":"4345_CR59","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1457887","author":"J Pfeifer Serrahima","year":"2024","unstructured":"Pfeifer Serrahima J, Schoenfeld K, K\u00fchnel I, Harwardt J, Macarr\u00f3n Palacios A, Pr\u00fcfer M, et al. Bispecific killer cell engagers employing species cross-reactive NKG2D binders redirect human and murine lymphocytes to ErbB2\/HER2-positive malignancies. Front Immunol. 2024. https:\/\/doi.org\/10.3389\/fimmu.2024.1457887.","journal-title":"Front Immunol"},{"issue":"19","key":"4345_CR60","doi-asserted-by":"publisher","first-page":"31959","DOI":"10.18632\/oncotarget.16657","volume":"8","author":"AB Raneros","year":"2017","unstructured":"Raneros AB, Minguela A, Rodriguez RM, Colado E, Bernal T, Anguita E, et al. Increasing TIMP3 expression by hypomethylating agents diminishes soluble MICA, MICB and ULBP2 shedding in acute myeloid leukemia, facilitating NK cell-mediated immune recognition. Oncotarget. 2017;8(19):31959\u201376.","journal-title":"Oncotarget"},{"issue":"2","key":"4345_CR61","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1042\/BJ20130194","volume":"454","author":"O Ashiru","year":"2013","unstructured":"Ashiru O, Lopez-Cobo S, Fernandez-Messina L, Pontes-Quero S, Pandolfi R, Reyburn HT, et al. A GPI anchor explains the unique biological features of the common NKG2D-ligand allele MICA* 008. Biochem J. 2013;454(2):295\u2013302.","journal-title":"Biochem J"},{"issue":"2","key":"4345_CR62","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1158\/0008-5472.CAN-09-1688","volume":"70","author":"O Ashiru","year":"2010","unstructured":"Ashiru O, Boutet P, Fern\u00e1ndez-Messina L, Ag\u00fcera-Gonz\u00e1lez S, Skepper JN, Val\u00e9s-G\u00f3mez M, et al. Natural killer cell cytotoxicity is suppressed by exposure to the human NKG2D ligand MICA* 008 that is shed by tumor cells in exosomes. Cancer Res. 2010;70(2):481\u20139.","journal-title":"Cancer Res"},{"issue":"5","key":"4345_CR63","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1038\/icb.2016.2","volume":"94","author":"L Fern\u00e1ndez-Messina","year":"2016","unstructured":"Fern\u00e1ndez-Messina L, Reyburn HT, Val\u00e9s\u2010G\u00f3mez M. A short half\u2010life of ULBP1 at the cell surface due to internalization and proteosomal degradation. Immunol Cell Biol. 2016;94(5):479\u201385.","journal-title":"Immunol Cell Biol"},{"issue":"7","key":"4345_CR64","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1002\/ijc.28174","volume":"133","author":"G Chitadze","year":"2013","unstructured":"Chitadze G, Lettau M, Bhat J, Wesch D, Steinle A, F\u00fcrst D, et al. Shedding of endogenous MHC class I-related chain molecules A and B from different human tumor entities: heterogeneous involvement of the a disintegrin and metalloproteases 10 and 17. Int J Cancer. 2013;133(7):1557\u201366.","journal-title":"Int J Cancer"},{"issue":"3","key":"4345_CR65","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/ijc.21382","volume":"118","author":"S Holdenrieder","year":"2006","unstructured":"Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A, Salih HR. Soluble MICA in malignant diseases. Int J Cancer. 2006;118(3):684\u20137.","journal-title":"Int J Cancer"},{"key":"4345_CR66","doi-asserted-by":"publisher","DOI":"10.1002\/mco2.70635","author":"Y Song","year":"2026","unstructured":"Song Y, Mo Y, Chen S, Chen Y, Zhang C, Deng S, et al. Immune exhaustion in chronic infection and cancer: signaling pathways and therapeutic interventions. MedComm. 2026. https:\/\/doi.org\/10.1002\/mco2.70635.","journal-title":"MedComm"},{"key":"4345_CR67","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbcan.2024.189162","author":"K Kang","year":"2024","unstructured":"Kang K, Lin X, Chen P, Liu H, Liu F, Xiong W, et al. T cell exhaustion in human cancers. Biochimica et Biophysica Acta (BBA). 2024. https:\/\/doi.org\/10.1016\/j.bbcan.2024.189162.","journal-title":"Biochimica et Biophysica Acta (BBA)"},{"key":"4345_CR68","doi-asserted-by":"publisher","DOI":"10.3892\/or.2024.8796","author":"S Huang","year":"2024","unstructured":"Huang S, Qin Z, Wang F, Kang Y, Ren B. A potential mechanism of tumor immune escape: regulation and application of soluble natural killer group 2 member D ligands (review). Oncol Rep. 2024. https:\/\/doi.org\/10.3892\/or.2024.8796.","journal-title":"Oncol Rep"},{"key":"4345_CR69","doi-asserted-by":"publisher","DOI":"10.3892\/or.2024.8796","author":"S Huang","year":"2024","unstructured":".Huang S, Qin Z, Wang F, Kang Y, Ren B. A potential mechanism of tumor immune escape: Regulation and application of soluble natural killer group 2 member D ligands. Oncology Reports. 2024 Aug 14;52(4):137. https:\/\/doi.org\/10.3892\/or.2024.8796","journal-title":"Oncology Reports."},{"key":"4345_CR70","doi-asserted-by":"publisher","first-page":"447","DOI":"10.3389\/fimmu.2020.00447","volume":"11","author":"A Zingoni","year":"2020","unstructured":"Zingoni A, Vulpis E, Loconte L, Santoni A. NKG2D ligand shedding in response to stress: role of ADAM10. Front Immunol. 2020;11:447.","journal-title":"Front Immunol"},{"key":"4345_CR71","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26072950","author":"K Yamane","year":"2025","unstructured":"Yamane K, Yamaguchi K, Teruya Y, Miyake N, Nakayama Y, Nonaka T, et al. ULBP2 promotes tumor progression by suppressing NKG2D-mediated anti-tumor immunity. Int J Mol Sci. 2025. https:\/\/doi.org\/10.3390\/ijms26072950.","journal-title":"Int J Mol Sci"},{"issue":"2","key":"4345_CR72","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1007\/s40199-020-00372-7","volume":"28","author":"M Moloudizargari","year":"2020","unstructured":"Moloudizargari M, Redegeld F, Asghari MH, Mosaffa N, Mortaz E. Long-chain polyunsaturated omega-3 fatty acids reduce multiple myeloma exosome-mediated suppression of NK cell cytotoxicity. Daru. 2020;28(2):647\u201359.","journal-title":"Daru"},{"issue":"22","key":"4345_CR73","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13225802","volume":"13","author":"Y Teng","year":"2021","unstructured":"Teng Y, Gao L, Loveless R, Rodrigo JP, Strojan P, Willems SM, et al. The hidden link of exosomes to head and neck cancer. Cancers. 2021;13(22):5802.","journal-title":"Cancers"},{"issue":"1","key":"4345_CR74","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/1471-2407-9-186","volume":"9","author":"T Garcia-Iglesias","year":"2009","unstructured":"Garcia-Iglesias T, del Toro-Arreola A, Albarran-Somoza B, del Toro-Arreola S, Sanchez-Hernandez PE, Ramirez-Due\u00f1as MG, Balderas-Pe\u00f1a LM, Bravo-Cuellar A, Ortiz-Lazareno PC, Daneri-Navarro A. Low NKp30, NKp46 and NKG2D expression and reduced cytotoxic activity on NK cells in cervical cancer and precursor lesions. BMC cancer. 2009 Jun 16;9(1):186. https:\/\/doi.org\/10.1186\/1471-2407-9-186","journal-title":"BMC cancer"},{"issue":"1","key":"4345_CR75","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/s41598-019-56542-4","volume":"10","author":"P Sharma","year":"2020","unstructured":"Sharma P, Diergaarde B, Ferrone S, Kirkwood JM, Whiteside TL. Melanoma cell-derived exosomes in plasma of melanoma patients suppress functions of immune effector cells. Sci Rep. 2020;10(1):92.","journal-title":"Sci Rep"},{"issue":"1","key":"4345_CR76","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-018-0372-z","volume":"16","author":"S L\u00f3pez-Cobo","year":"2018","unstructured":"L\u00f3pez-Cobo S, Campos-Silva C, Moyano A, Oliveira-Rodr\u00edguez M, Paschen A, Y\u00e1\u00f1ez-M\u00f3 M, et al. Immunoassays for scarce tumour-antigens in exosomes: detection of the human NKG2D-ligand, MICA, in tetraspanin-containing nanovesicles from melanoma. J Nanobiotechnol. 2018;16(1):47.","journal-title":"J Nanobiotechnol"},{"issue":"3","key":"4345_CR77","doi-asserted-by":"publisher","first-page":"206","DOI":"10.1016\/j.bcmd.2005.03.003","volume":"34","author":"A Clayton","year":"2005","unstructured":"Clayton A, Tabi Z. Exosomes and the MICA-NKG2D system in cancer. Blood Cells Mol Dis. 2005;34(3):206\u201313.","journal-title":"Blood Cells Mol Dis"},{"key":"4345_CR78","doi-asserted-by":"publisher","first-page":"997806","DOI":"10.3389\/fimmu.2022.997806","volume":"13","author":"D Mele","year":"2022","unstructured":"Mele D, Pessino G, Trisolini G, Luchena A, Benazzo M, Morbini P, et al. Impaired intratumoral natural killer cell function in head and neck carcinoma. Front Immunol. 2022;13:997806.","journal-title":"Front Immunol"},{"key":"4345_CR79","doi-asserted-by":"publisher","first-page":"1442673","DOI":"10.3389\/fimmu.2024.1442673","volume":"15","author":"S Dong","year":"2024","unstructured":"Dong S, Zhao M, Zhu J, Li T, Yan M, Xing K, et al. Natural killer cells: a future star for immunotherapy of head and neck squamous cell carcinoma. Front Immunol. 2024;15:1442673.","journal-title":"Front Immunol"},{"issue":"1","key":"4345_CR80","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1093\/neuonc\/nop009","volume":"12","author":"CA Crane","year":"2010","unstructured":"Crane CA, Han SJ, Barry JJ, Ahn BJ, Lanier LL, Parsa AT. TGF-\u03b2 downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. Neuro-oncology. 2010 Jan 1;12(1):7-13. https:\/\/doi.org\/10.1093\/neuonc\/nop009","journal-title":"Neuro-oncology."},{"key":"4345_CR81","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3389\/fimmu.2017.00523","volume":"8","author":"AB Guimar\u00e3es-Costa","year":"2017","unstructured":"Guimar\u00e3es-Costa AB, Rochael NC, Oliveira F, Echevarria-Lima J, Saraiva EM. Neutrophil extracellular traps reprogram IL-4\/GM-CSF-induced monocyte differentiation to anti-inflammatory macrophages. Front Immunol. 2017;8:523.","journal-title":"Front Immunol"},{"issue":"11","key":"4345_CR82","doi-asserted-by":"publisher","first-page":"e1055993","DOI":"10.1080\/2162402X.2015.1055993","volume":"4","author":"S Kl\u00f6\u00df","year":"2015","unstructured":"Kl\u00f6\u00df S, Chambron N, Gardlowski T, Arseniev L, Koch J, Esser R, et al. Increased sMICA and TGF\u03b21 levels in HNSCC patients impair NKG2D-dependent functionality of activated NK cells. Oncoimmunology. 2015;4(11):e1055993.","journal-title":"Oncoimmunology"},{"issue":"2","key":"4345_CR83","doi-asserted-by":"publisher","first-page":"961","DOI":"10.4049\/jimmunol.1203328","volume":"191","author":"R Mishra","year":"2013","unstructured":"Mishra R, Polic B, Welsh RM, Szomolanyi-Tsuda E. Inflammatory cytokine-mediated evasion of virus-induced tumors from NK cell control. J Immunol. 2013;191(2):961\u201370.","journal-title":"J Immunol"},{"key":"4345_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/ijms241914928","author":"J Xing","year":"2023","unstructured":"Xing J, Zhang J, Wang J. The immune regulatory role of adenosine in the tumor microenvironment. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms241914928.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"4345_CR85","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1111\/imm.12037","volume":"138","author":"SA Gerber","year":"2013","unstructured":"Gerber SA, Sorensen EW, Sedlacek AL, Lim JYH, Skrombolas D, Frelinger JG, et al. Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology. 2013;138(3):280\u201392.","journal-title":"Immunology"},{"issue":"8","key":"4345_CR86","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1111\/jop.13185","volume":"50","author":"M Ivanova","year":"2021","unstructured":"Ivanova M, Al Hadra B, Yordanov S, Lesichkova S, Stoyanov H, Shivarov V, et al. Associations of high-resolution\u2010typing\u2010defined MICA and MICB polymorphisms, and the levels of soluble MICA and MICB with Oral Squamous Cell Carcinoma in Bulgarian patients. J Oral Pathol Med. 2021;50(8):758\u201365.","journal-title":"J Oral Pathol Med"},{"key":"4345_CR87","doi-asserted-by":"publisher","DOI":"10.1016\/j.oraloncology.2021.105256","volume":"116","author":"R Tani","year":"2021","unstructured":"Tani R, Ito N, Matsui K, Yamasaki S, Hamada A, Tokumaru K, et al. MICA A5. 1 homozygous genotype is associated with a risk for early-onset oral cancer. Oral Oncol. 2021;116:105256.","journal-title":"Oral Oncol"},{"issue":"5","key":"4345_CR88","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1080\/08820139.2019.1690506","volume":"49","author":"A Ben Chaaben","year":"2020","unstructured":"Ben Chaaben A, Ouni N, Douik H, Ayari F, Abaza H, Mamoghli T, et al. Soluble MICA and anti-MICA antibodies as biomarkers of nasopharyngeal carcinoma disease. Immunol Investig. 2020;49(5):498\u2013509.","journal-title":"Immunol Investig"},{"issue":"8","key":"4345_CR89","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0202224","volume":"13","author":"J-Y Chen","year":"2018","unstructured":"Chen J-Y, Chang C-C, Huang Y-S, Kuo H-Y, Chen T-Y, Wang C-W, et al. Persistently elevated soluble MHC class I polypeptide-related sequence A and transforming growth factor-\u03b21 levels are poor prognostic factors in head and neck squamous cell carcinoma after definitive chemoradiotherapy. PLoS One. 2018;13(8):e0202224.","journal-title":"PLoS One"},{"issue":"1","key":"4345_CR90","doi-asserted-by":"publisher","first-page":"25645","DOI":"10.1038\/s41598-024-77042-0","volume":"14","author":"B Dong","year":"2024","unstructured":"Dong B, Hua J, Ma S, Wang L, Xiao H, Qiao X, et al. Causal associations of MICB, CTSA, and MMP9 proteins with oral cancer: Mendelian randomization study. Sci Rep. 2024;14(1):25645.","journal-title":"Sci Rep"},{"issue":"1","key":"4345_CR91","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-024-05549-1","volume":"22","author":"B Tang","year":"2024","unstructured":"Tang B, Guo M, Zhai Y, Zhang K, Ni K, Zhang Y, et al. Human esophageal cancer stem-like cells escape the cytotoxicity of natural killer cells via down-regulation of ULBP-1. J Transl Med. 2024;22(1):737.","journal-title":"J Transl Med"},{"issue":"2","key":"4345_CR92","doi-asserted-by":"publisher","first-page":"e001523","DOI":"10.1136\/jitc-2020-001523","volume":"8","author":"AJ Charap","year":"2020","unstructured":"Charap AJ, Enokida T, Brody R, Sfakianos J, Miles B, Bhardwaj N, et al. Landscape of natural killer cell activity in head and neck squamous cell carcinoma. J Immunother Cancer. 2020;8(2):e001523.","journal-title":"J Immunother Cancer"},{"issue":"6","key":"4345_CR93","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1158\/2326-6066.CIR-15-0098","volume":"3","author":"LL Lanier","year":"2015","unstructured":"Lanier LL. NKG2D receptor and its ligands in host defense. Cancer Immunol Res. 2015;3(6):575\u201382.","journal-title":"Cancer Immunol Res"},{"key":"4345_CR94","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.713158","volume":"12","author":"MB Fuertes","year":"2021","unstructured":"Fuertes MB, Domaica CI, Zwirner NW. Leveraging NKG2D ligands in immuno-oncology. Front Immunol. 2021;12:713158.","journal-title":"Front Immunol"},{"issue":"9","key":"4345_CR95","doi-asserted-by":"publisher","first-page":"e1476817","DOI":"10.1080\/2162402X.2018.1476817","volume":"7","author":"F Bochen","year":"2018","unstructured":"Bochen F, Balensiefer B, K\u00f6rner S, Bittenbring JT, Neumann F, Koch A, et al. Vitamin D deficiency in head and neck cancer patients\u2013prevalence, prognostic value and impact on immune function. Oncoimmunology. 2018;7(9):e1476817.","journal-title":"Oncoimmunology"},{"key":"4345_CR96","doi-asserted-by":"crossref","unstructured":"Han Y, Xie W, Song D-G, Powell DJ Jr. Control of triple-negative breast cancer using ex vivo self-enriched, costimulated NKG2D CAR T cells. J Hematol Oncol. 2018;11(1):92.","DOI":"10.1186\/s13045-018-0635-z"},{"issue":"1","key":"4345_CR97","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-020-00896-0","volume":"13","author":"F Basher","year":"2020","unstructured":"Basher F, Dhar P, Wang X, Wainwright DA, Zhang B, Sosman J, et al. Antibody targeting tumor-derived soluble NKG2D ligand sMIC reprograms NK cell homeostatic survival and function and enhances melanoma response to PDL1 blockade therapy. J Hematol Oncol. 2020;13(1):74.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"4345_CR98","doi-asserted-by":"publisher","first-page":"9","DOI":"10.3390\/immuno5010009","volume":"5","author":"E Boneva","year":"2025","unstructured":"Boneva E, Shivarov V, Ivanova M. A concise review of the role of the NKG2D receptor and its ligands in cancer. Immuno. 2025;5(1):9.","journal-title":"Immuno"},{"issue":"8","key":"4345_CR99","doi-asserted-by":"publisher","DOI":"10.1038\/s41408-021-00537-w","volume":"11","author":"A Leivas","year":"2021","unstructured":"Leivas A, Valeri A, C\u00f3rdoba L, Garc\u00eda-Ortiz A, Ortiz A, S\u00e1nchez-Vega L, et al. NKG2D-CAR-transduced natural killer cells efficiently target multiple myeloma. Blood Cancer J. 2021;11(8):146.","journal-title":"Blood Cancer J"},{"issue":"11","key":"4345_CR100","doi-asserted-by":"publisher","first-page":"e005632","DOI":"10.1136\/jitc-2022-005632","volume":"10","author":"M Crist","year":"2022","unstructured":"Crist M, Yaniv B, Palackdharry S, Lehn MA, Medvedovic M, Stone T, et al. Metformin increases natural killer cell functions in head and neck squamous cell carcinoma through CXCL1 inhibition. J Immunother Cancer. 2022;10(11):e005632.","journal-title":"J Immunother Cancer"},{"key":"4345_CR101","doi-asserted-by":"publisher","first-page":"387","DOI":"10.3389\/fimmu.2017.00387","volume":"8","author":"S Weil","year":"2017","unstructured":"Weil S, Memmer S, Lechner A, Huppert V, Giannattasio A, Becker T, et al. Natural killer group 2D ligand depletion reconstitutes natural killer cell immunosurveillance of head and neck squamous cell carcinoma. Front Immunol. 2017;8:387.","journal-title":"Front Immunol"},{"key":"4345_CR102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2015.00543","volume":"6","author":"S Kl\u00f6ss","year":"2015","unstructured":"Kl\u00f6ss S, Chambron N, Gardlowski T, Weil S, Koch J, Esser R, et al. Cetuximab reconstitutes pro-inflammatory cytokine secretions and tumor-infiltrating capabilities of sMICA-inhibited NK cells in HNSCC tumor spheroids. Front Immunol. 2015;6:543.","journal-title":"Front Immunol"},{"issue":"21","key":"4345_CR103","doi-asserted-by":"publisher","first-page":"6419","DOI":"10.1158\/1078-0432.CCR-07-0865","volume":"13","author":"JM Roda","year":"2007","unstructured":"Roda JM, Joshi T, Butchar JP, McAlees JW, Lehman A, Tridandapani S, et al. The activation of natural killer cell effector functions by cetuximab-coated, epidermal growth factor receptor\u2013positive tumor cells is enhanced by cytokines. Clin Cancer Res. 2007;13(21):6419\u201328.","journal-title":"Clin Cancer Res"},{"issue":"9","key":"4345_CR104","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.jcyt.2022.05.004","volume":"24","author":"EK Jung","year":"2022","unstructured":"Jung EK, Chu T-H, Vo M-C, Nguyen HPQ, Lee DH, Lee JK, et al. Natural killer cells have a synergistic anti-tumor effect in combination with chemoradiotherapy against head and neck cancer. Cytotherapy. 2022;24(9):905\u201315.","journal-title":"Cytotherapy"},{"issue":"14","key":"4345_CR105","first-page":"4023","volume":"62","author":"D Li","year":"2002","unstructured":"Li D, Ronson B, Guo M, Liu S, Bishop JS, Van Echo DA, et al. Interleukin 2 gene transfer prevents NKG2D suppression and enhances antitumor efficacy in combination with cisplatin for head and neck squamous cell cancer. Cancer Res. 2002;62(14):4023\u20138.","journal-title":"Cancer Res"},{"issue":"11","key":"4345_CR106","doi-asserted-by":"publisher","first-page":"2200","DOI":"10.1158\/0008-5472.CAN-14-2788","volume":"75","author":"H-B Jie","year":"2015","unstructured":"Jie H-B, Schuler PJ, Lee SC, Srivastava RM, Argiris A, Ferrone S, et al. CTLA-4\u2009+\u2009regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis. Cancer Res. 2015;75(11):2200\u201310.","journal-title":"Cancer Res"},{"issue":"8","key":"4345_CR107","doi-asserted-by":"publisher","first-page":"e007141","DOI":"10.1136\/jitc-2023-007141","volume":"11","author":"JM Johnson","year":"2023","unstructured":"Johnson JM, Vathiotis IA, Harshyne LA, Ali A, Ad VB, Axelrod R, et al. Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck. J Immunother Cancer. 2023;11(8):e007141.","journal-title":"J Immunother Cancer"},{"issue":"8","key":"4345_CR108","doi-asserted-by":"publisher","first-page":"5541","DOI":"10.4049\/jimmunol.175.8.5541","volume":"175","author":"S Dasgupta","year":"2005","unstructured":"Dasgupta S, Bhattacharya-Chatterjee M, O\u2019Malley BW, Chatterjee SK. Inhibition of NK cell activity through TGF-\u03b21 by down-regulation of NKG2D in a murine model of head and neck cancer. J Immunol. 2005;175(8):5541\u201350.","journal-title":"J Immunol"},{"issue":"6","key":"4345_CR109","first-page":"5335","volume":"20","author":"L Hu","year":"2019","unstructured":"Hu L, Li H, Lee ED, Grandis JR, Bauman JE, Johnson DE. Gene targets of sulforaphane in head and neck squamous cell carcinoma. Mol Med Rep. 2019;20(6):5335\u201344.","journal-title":"Mol Med Rep"},{"key":"4345_CR110","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101150","author":"J Gadwa","year":"2023","unstructured":"Gadwa J, Amann M, Bickett TE, Knitz MW, Darragh LB, Piper M, et al. Selective targeting of IL2R\u03b2\u03b3 combined with radiotherapy triggers CD8- and NK-mediated immunity,abrogating metastasis in HNSCC. Cell Rep Med. 2023. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101150.","journal-title":"Cell Rep Med"},{"issue":"10","key":"4345_CR111","doi-asserted-by":"publisher","first-page":"4596","DOI":"10.1111\/jcmm.16253","volume":"25","author":"H Wang","year":"2021","unstructured":"Wang H, Nan S, Wang Y, Xu C. CDX2 enhances natural killer cell\u2013mediated immunotherapy against head and neck squamous cell carcinoma through up-regulating CXCL14. J Cell Mol Med. 2021;25(10):4596\u2013607.","journal-title":"J Cell Mol Med"},{"issue":"32","key":"4345_CR112","doi-asserted-by":"publisher","first-page":"e34761","DOI":"10.1097\/MD.0000000000034761","volume":"102","author":"H Tan","year":"2023","unstructured":"Tan H, Yang H, Qian J, Liu S, Yan D, Wei L, et al. Involvement of KLRK1 in immune infiltration of head and neck squamous cell carcinoma correlates with favorable prognosis. Medicine. 2023;102(32):e34761.","journal-title":"Medicine"},{"key":"4345_CR113","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.oraloncology.2019.01.017","volume":"90","author":"J Friedman","year":"2019","unstructured":"Friedman J, Padget M, Lee J, Schlom J, Hodge J, Allen C. Direct and antibody-dependent cell-mediated cytotoxicity of head and neck squamous cell carcinoma cells by high-affinity natural killer cells. Oral Oncol. 2019;90:38\u201344.","journal-title":"Oral Oncol"},{"issue":"15suppl","key":"4345_CR114","doi-asserted-by":"publisher","first-page":"6037","DOI":"10.1200\/JCO.2019.37.15_suppl.6037","volume":"37","author":"V Karivedu","year":"2019","unstructured":"Karivedu V, Yaniv B, Asman M, Palackdharry S, Gulati S, Jandarov R, et al. Metformin treatment of locally advanced head and neck squamous cell carcinoma (LAHNSCC) patients induces an anti-tumorigenic immune response. J Clin Oncol. 2019;37(15suppl):6037.","journal-title":"J Clin Oncol"},{"issue":"3","key":"4345_CR115","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jcyt.2023.11.002","volume":"26","author":"EK Jung","year":"2024","unstructured":"Jung EK, Chu T-H, Kim S-A, Vo M-C, Nguyen V-T, Lee K-H, et al. Efficacy of natural killer cell therapy combined with chemoradiotherapy in murine models of head and neck squamous cell carcinoma. Cytotherapy. 2024;26(3):242\u201351.","journal-title":"Cytotherapy"},{"issue":"14","key":"4345_CR116","first-page":"4023","volume":"62","author":"D Li","year":"2002","unstructured":"Li D, Ronson B, Guo M, Liu S, Bishop JS, Van Echo DA, et al. Interleukin 2 Gene Transfer Prevents NKG2D Suppression and Enhances Antitumor Efficacy in Combination with Cisplatin for Head and Neck Squamous Cell Cancer1. Cancer Res. 2002;62(14):4023\u20138.","journal-title":"Cancer Res"},{"issue":"16","key":"4345_CR117","doi-asserted-by":"publisher","first-page":"3034","DOI":"10.1002\/cncr.28150","volume":"119","author":"EA Mroz","year":"2013","unstructured":"Mroz EA, Tward AD, Pickering CR, Myers JN, Ferris RL, Rocco JW. High intratumor genetic heterogeneity is related to worse outcome in patients with head and neck squamous cell carcinoma. Cancer. 2013;119(16):3034\u201342.","journal-title":"Cancer"},{"key":"4345_CR118","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.713158","volume":"12","author":"M Fuertes","year":"2021","unstructured":"Fuertes M, Domaica C, Zwirner N. Leveraging NKG2D ligands in immuno-oncology. Front Immunol. 2021;12:713158.","journal-title":"Front Immunol"},{"issue":"4","key":"4345_CR119","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1182\/blood-2003-01-0019","volume":"102","author":"HR Salih","year":"2003","unstructured":"Salih HR, Antropius H, Gieseke F, Lutz SZ, Kanz L, Rammensee H-G, et al. Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia. Blood. 2003;102(4):1389\u201396.","journal-title":"Blood"},{"issue":"6908","key":"4345_CR120","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1038\/nature01112","volume":"419","author":"V Groh","year":"2002","unstructured":"Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002;419(6908):734\u20138.","journal-title":"Nature"},{"issue":"10","key":"4345_CR121","first-page":"4097","volume":"30","author":"S Tamaki","year":"2010","unstructured":"Tamaki S, Kawakami M, Ishitani A, Kawashima W, Kasuda S, Yamanaka Y, et al. Soluble MICB serum levels correlate with disease stage and survival rate in patients with oral squamous cell carcinoma. Anticancer Res. 2010;30(10):4097\u2013101.","journal-title":"Anticancer Res"},{"issue":"6","key":"4345_CR122","doi-asserted-by":"publisher","first-page":"e126908","DOI":"10.1172\/jci.insight.126908","volume":"4","author":"M Yarchoan","year":"2019","unstructured":"Yarchoan M, Albacker LA, Hopkins AC, Montesion M, Murugesan K, Vithayathil TT, et al. PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers. JCI insight. 2019;4(6):e126908.","journal-title":"JCI insight"},{"key":"4345_CR123","doi-asserted-by":"publisher","first-page":"e54854","DOI":"10.7554\/eLife.54854","volume":"9","author":"Y Robbins","year":"2020","unstructured":"Robbins Y, Greene S, Friedman J, Clavijo PE, Van Waes C, Fabian KP, et al. Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells. Elife. 2020;9:e54854.","journal-title":"Elife"},{"issue":"7","key":"4345_CR124","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.medj.2023.04.004","volume":"4","author":"J Goulding","year":"2023","unstructured":"Goulding J, Yeh W-I, Hancock B, Blum R, Xu T, Yang B-H, et al. A chimeric antigen receptor uniquely recognizing MICA\/B stress proteins provides an effective approach to target solid tumors. Med. 2023;4(7):457\u201377. e8.","journal-title":"Med"},{"key":"4345_CR125","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2023.116095","author":"S Mestiri","year":"2024","unstructured":"Mestiri S, El-Ella DMA, Fernandes Q, Bedhiafi T, Almoghrabi S, Akbar S, et al. The dynamic role of immune checkpoint molecules in diagnosis, prognosis, and treatment of head and neck cancers. Biomed Pharmacother. 2024. https:\/\/doi.org\/10.1016\/j.biopha.2023.116095.","journal-title":"Biomed Pharmacother"},{"issue":"5","key":"4345_CR126","doi-asserted-by":"publisher","first-page":"e1123367","DOI":"10.1080\/2162402X.2015.1123367","volume":"5","author":"MR Zocchi","year":"2016","unstructured":"Zocchi MR, Camodeca C, Nuti E, Rossello A, Ven\u00e8 R, Tosetti F, et al. ADAM10 new selective inhibitors reduce NKG2D ligand release sensitizing Hodgkin lymphoma cells to NKG2D-mediated killing. Oncoimmunology. 2016;5(5):e1123367.","journal-title":"Oncoimmunology"},{"issue":"3","key":"4345_CR127","first-page":"661","volume":"19","author":"Y Xu","year":"2018","unstructured":"Xu Y, Zhou R, Huang C, Zhang M, Li J, Zong J, et al. Analysis of the expression of surface receptors on NK cells and NKG2D on immunocytes in peripheral blood of patients with nasopharyngeal carcinoma. Asian Pac J cancer prevention: APJCP. 2018;19(3):661.","journal-title":"Asian Pac J cancer prevention: APJCP"},{"issue":"1","key":"4345_CR128","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2020.1747345","volume":"9","author":"SK Bisheshar","year":"2020","unstructured":"Bisheshar SK, De Ruiter EJ, Devriese LA, Willems SM. The prognostic role of NK cells and their ligands in squamous cell carcinoma of the head and neck: a systematic review and meta-analysis. Oncoimmunology. 2020;9(1):1747345.","journal-title":"Oncoimmunology"},{"issue":"26","key":"4345_CR129","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.14917","volume":"8","author":"Y Xu","year":"2017","unstructured":"Xu Y, Zhou L, Zong J, Ye Y, Chen G, Chen Y, et al. Decreased expression of the NKG2D ligand ULBP4 may be an indicator of poor prognosis in patients with nasopharyngeal carcinoma. Oncotarget. 2017;8(26):42007.","journal-title":"Oncotarget"},{"issue":"1","key":"4345_CR130","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41368-021-00131-7","volume":"13","author":"A Elmusrati","year":"2021","unstructured":"Elmusrati A, Wang J, Wang C-Y. Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma. Int J Oral Sci. 2021;13(1):24.","journal-title":"Int J Oral Sci"},{"issue":"9","key":"4345_CR131","doi-asserted-by":"publisher","first-page":"4468","DOI":"10.4049\/jimmunol.1102643","volume":"188","author":"BW Wortham","year":"2012","unstructured":"Wortham BW, Eppert BL, Motz GT, Flury JL, Orozco-Levi M, Hoebe K, et al. NKG2D mediates NK cell hyperresponsiveness and influenza-induced pathologies in a mouse model of chronic obstructive pulmonary disease. J Immunol. 2012;188(9):4468\u201375.","journal-title":"J Immunol"}],"container-title":["Cancer Cell International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12935-026-04345-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12935-026-04345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T17:02:41Z","timestamp":1784566961000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12935-026-04345-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,25]]},"references-count":131,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4345"],"URL":"https:\/\/doi.org\/10.1186\/s12935-026-04345-9","relation":{},"ISSN":["1475-2867"],"issn-type":[{"value":"1475-2867","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,25]]},"assertion":[{"value":"2 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All authors provided consent to publish the manuscript.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"267"}}